Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAI plus Lenvatinib in Advanced HCC
NCT04053985Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04053985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04053985.